Perceptive Advisors LLC lessened its stake in Abeona Therapeutics Inc (NASDAQ:ABEO) by 49.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 59,662 shares of the biopharmaceutical company’s stock after selling 57,238 shares during the quarter. Perceptive Advisors LLC’s holdings in Abeona Therapeutics were worth $946,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Northern Trust Corp lifted its holdings in shares of Abeona Therapeutics by 406.3% in the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock worth $1,649,000 after buying an additional 206,775 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Abeona Therapeutics in the fourth quarter worth $346,000. TIAA CREF Investment Management LLC purchased a new position in shares of Abeona Therapeutics in the second quarter worth $430,000. EAM Investors LLC raised its stake in Abeona Therapeutics by 50.3% during the fourth quarter. EAM Investors LLC now owns 221,175 shares of the biopharmaceutical company’s stock valued at $3,506,000 after purchasing an additional 74,002 shares in the last quarter. Finally, Teachers Advisors LLC purchased a new stake in Abeona Therapeutics during the second quarter valued at $284,000. 62.64% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts recently issued reports on the stock. Maxim Group reaffirmed a “buy” rating and set a $35.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, February 7th. Jefferies Group reaffirmed a “buy” rating and set a $28.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, November 22nd. HC Wainwright set a $30.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Thursday, February 8th. ValuEngine raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BidaskClub raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Abeona Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $27.11.
TRADEMARK VIOLATION WARNING: “Abeona Therapeutics Inc (ABEO) Shares Sold by Perceptive Advisors LLC” was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2018/03/13/abeona-therapeutics-inc-abeo-shares-sold-by-perceptive-advisors-llc.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc (NASDAQ:ABEO).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.